Pages that link to "Q37559690"
Jump to navigation
Jump to search
The following pages link to Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy (Q37559690):
Displaying 41 items.
- Management of insect sting hypersensitivity: an update (Q24631273) (← links)
- Mast Cell Clonal Disorders: Classification, Diagnosis and Management (Q28070386) (← links)
- Anaphylaxis to insect venom allergens: role of molecular diagnostics (Q28088677) (← links)
- Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement (Q30371972) (← links)
- Hymenoptera Allergy and Mast Cell Activation Syndromes (Q33166619) (← links)
- Mast cell activation syndromes: definition and classification. (Q34035582) (← links)
- Anaphylaxis caused by Hymenoptera stings: from epidemiology to treatment (Q34192110) (← links)
- Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity (Q34735017) (← links)
- Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT. (Q35153623) (← links)
- Insect stings: clinical features and management (Q35907982) (← links)
- Single venom-based immunotherapy effectively protects patients with double positive tests to honey bee and Vespula venom (Q37355616) (← links)
- Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. (Q37810130) (← links)
- Clinical immunology review series: an approach to desensitization (Q37822834) (← links)
- Hymenoptera Venom Immunotherapy (Q37842330) (← links)
- Management of occupational Hymenoptera allergy (Q37849105) (← links)
- Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis. (Q37873485) (← links)
- Insect allergy (Q37931150) (← links)
- Diffuse cutaneous mastocytosis: analysis of 10 cases and a brief review of the literature (Q37957219) (← links)
- Risk factors and management of severe life-threatening anaphylaxis in patients with clonal mast cell disorders (Q38202204) (← links)
- Spectrum of mast cell activation disorders (Q38208377) (← links)
- Gene expression analysis predicts insect venom anaphylaxis in indolent systemic mastocytosis. (Q38504083) (← links)
- Immunology of Bee Venom (Q39096069) (← links)
- NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation. (Q39348704) (← links)
- Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology (Q39779573) (← links)
- The Epidemiology of Anaphylaxis (Q40552110) (← links)
- Honeybee venom immunotherapy: a comparative study using purified and nonpurified aqueous extracts in patients with normal Basal serum tryptase concentrations (Q40582052) (← links)
- Added sensitivity of component-resolved diagnosis in hymenoptera venom-allergic patients with elevated serum tryptase and/or mastocytosis. (Q40808699) (← links)
- Mastocytosis in children and adults: clinical disease heterogeneity (Q42243338) (← links)
- Gene expression analysis in allergology: the prediction of Hymenoptera venom allergy severity and treatment efficacy. (Q42923350) (← links)
- Predictors of clinical effectiveness of Hymenoptera venom immunotherapy. (Q44459579) (← links)
- Presentation of untreated systemic mastocytosis as recurrent, pulseless-electrical-activity cardiac arrests resistant to cardiac pacemaker (Q44928919) (← links)
- Basophil response and the induction of a tolerance in venom immunotherapy: a long-term sting challenge study (Q48705226) (← links)
- Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis (Q50871797) (← links)
- Self-medication of anaphylactic reactions due to Hymenoptera stings-an EAACI Task Force Consensus Statement (Q51533907) (← links)
- Immunological and clinical factors associated with adverse systemic reactions during the build-up phase of honeybee venom immunotherapy. (Q51624794) (← links)
- Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experience. (Q52731268) (← links)
- Angiotensin-converting enzyme inhibitors do not impair the safety of Hymenoptera venom immunotherapy build-up phase. (Q52765228) (← links)
- [Sting challenge: indications and execution]. (Q52779212) (← links)
- The Role of KIT Mutations in Anaphylaxis. (Q64889470) (← links)
- Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders? (Q92447847) (← links)
- Risk factors in Hymenoptera venom allergy (Q92875065) (← links)